Andrew Redfern
Impact in
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- Cancer Genomics and Diagnostics
- Oncology top 5%
- Cancer Cells and Metastasis
Papers in
- Oncology 49
- HER2/EGFR in Cancer Research 12
- Cancer Treatment and Pharmacology 11
- Cancer Cells and Metastasis 9
- Cancer Immunotherapy and Biomarkers 9
-
- Advanced Breast Cancer Therapies 14
- Co-authors
- Erik W. Thompson (13 shared papers)Dingcheng Gao (1 shared paper)Elizabeth D. Williams (1 shared paper)Pilar Blancafort (6 shared papers)Edina Wang (4 shared papers)Anabel Sorolla (4 shared papers)Emily Golden (4 shared papers)Peter J. Leedman (4 shared papers)
- Journals
- Journal of Clinical Oncology (12 papers)Cancer Research (12 papers)Annals of Oncology (3 papers)British Journal of Urology (2 papers)Blood (2 papers)
- Partner nations
- AustraliaUnited StatesUnited Kingdom
In The Last Decade
Andrew Redfern
96 papers receiving 1.7k citations
Peers
Comparison fields: 5 of 107
- Cancer Research 365
- Oncology 587
- Molecular Biology 684
- Immunology 198
- Pulmonary and Respiratory Medicine 226
Countries citing papers authored by Andrew Redfern
This map shows the geographic impact of Andrew Redfern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Redfern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Redfern more than expected).
Fields of papers citing papers by Andrew Redfern
This network shows the impact of papers produced by Andrew Redfern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Redfern. The network helps show where Andrew Redfern may publish in the future.
Co-authors
The 25 scholars most cited alongside Andrew Redfern, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 102 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 314 | |
| 2 | 2013 | 124 | |
| 3 | 2020 | 124 | |
| 4 | 2006 | 103 | |
| 5 | 2019 | 76 | |
| 6 | 2000 | 60 | |
| 7 | 2015 | 58 | |
| 8 | 2020 | 52 | |
| 9 | 2013 | 49 | |
| 10 | 2015 | 43 | |
| 11 | 2018 | 42 | |
| 12 | 2019 | 41 | |
| 13 | 2019 | 41 | |
| 14 | 2021 | 40 | |
| 15 | 2021 | 33 | |
| 16 | 2019 | 31 | |
| 17 | 2022 | 30 | |
| 18 | 2016 | 30 | |
| 19 | 2014 | 27 | |
| 20 | 2018 | 24 |
About Andrew Redfern
Andrew Redfern is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Surgery, having authored 102 papers that have together received 1.7k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (16 papers), Advanced Breast Cancer Therapies (14 papers), HER2/EGFR in Cancer Research (12 papers), Cancer Treatment and Pharmacology (11 papers), Cancer Cells and Metastasis (9 papers), Bladder and Urothelial Cancer Treatments (9 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Cancer Genomics and Diagnostics (7 papers). The work is most often cited by research in Cancer Research (365 citations), Oncology (587 citations), Molecular Biology (684 citations), Immunology (198 citations) and Pulmonary and Respiratory Medicine (226 citations). Andrew Redfern has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Erik W. Thompson, Dingcheng Gao, Elizabeth D. Williams, Pilar Blancafort, Edina Wang, Anabel Sorolla, Emily Golden, Peter J. Leedman, Lisa M. Stuart and Michael R. Epis. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, British Journal of Urology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.